These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34324082)

  • 41. Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis.
    Prather C; Adams E; Zentgraf W
    Am J Health Syst Pharm; 2020 Nov; 77(23):1949-1956. PubMed ID: 32880646
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preoperative bone health assessment and optimization in spine surgery.
    Anderson PA; Kadri A; Hare KJ; Binkley N
    Neurosurg Focus; 2020 Aug; 49(2):E2. PubMed ID: 32738805
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
    Cosman F; Crittenden DB; Adachi JD; Binkley N; Czerwinski E; Ferrari S; Hofbauer LC; Lau E; Lewiecki EM; Miyauchi A; Zerbini CA; Milmont CE; Chen L; Maddox J; Meisner PD; Libanati C; Grauer A
    N Engl J Med; 2016 Oct; 375(16):1532-1543. PubMed ID: 27641143
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased Serum 25(OH)D
    Nakamura Y; Uchiyama S; Kamimura M; Ikegami S; Komatsu M; Kato H
    Tohoku J Exp Med; 2017 Jul; 242(3):241-246. PubMed ID: 28740036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials.
    Liu Y; Cao Y; Zhang S; Zhang W; Zhang B; Tang Q; Li Z; Wu J
    Climacteric; 2018 Apr; 21(2):189-195. PubMed ID: 29424257
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis.
    Graeff C; Campbell GM; Peña J; Borggrefe J; Padhi D; Kaufman A; Chang S; Libanati C; Glüer CC
    Bone; 2015 Dec; 81():364-369. PubMed ID: 26232375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
    Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
    Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Romosozumab and Sequential Therapy in Postmenopausal Osteoporosis.
    Slaton RM; Boyd K; Iranikhah M
    Sr Care Pharm; 2020 Jul; 35(7):297-308. PubMed ID: 32600508
    [No Abstract]   [Full Text] [Related]  

  • 51. Screening osteoporotic femoral neck without measuring bone mineral density with the use of tartrate resistant acid phosphatase-5b and serum-creatinine-to-cystatin C ratio in Japanese postmenopausal women.
    Yoshii I; Chijiwa T; Sawada N
    J Orthop Sci; 2020 Jul; 25(4):671-676. PubMed ID: 31337577
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
    Langdahl BL; Libanati C; Crittenden DB; Bolognese MA; Brown JP; Daizadeh NS; Dokoupilova E; Engelke K; Finkelstein JS; Genant HK; Goemaere S; Hyldstrup L; Jodar-Gimeno E; Keaveny TM; Kendler D; Lakatos P; Maddox J; Malouf J; Massari FE; Molina JF; Ulla MR; Grauer A
    Lancet; 2017 Sep; 390(10102):1585-1594. PubMed ID: 28755782
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonresponder Considerations for Romosozumab Treatment.
    Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Shimamoto S; Kodama Y; Kato Y
    Calcif Tissue Int; 2023 Aug; 113(2):157-165. PubMed ID: 37138124
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Romosozumab: A Review in Postmenopausal Osteoporosis.
    Paik J; Scott LJ
    Drugs Aging; 2020 Nov; 37(11):845-855. PubMed ID: 32909197
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between bone mineral density and biochemical markers of bone turnover in hemodialysis patients.
    Sit D; Kadiroglu AK; Kayabasi H; Atay AE; Yilmaz Z; Yilmaz ME
    Adv Ther; 2007; 24(5):987-95. PubMed ID: 18029324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
    Hasegawa E; Ito S; Takai C; Kobayashi D; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Intern Med; 2018 Aug; 57(15):2169-2178. PubMed ID: 29607978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Romosozumab used to treat a patient with cystic fibrosis-related osteoporosis.
    Crow HM; Graves L; Anabtawi A
    Am J Med Sci; 2022 Oct; 364(4):461-465. PubMed ID: 35469767
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Romosozumab: a novel bone anabolic treatment option for osteoporosis?
    Kerschan-Schindl K
    Wien Med Wochenschr; 2020 Apr; 170(5-6):124-131. PubMed ID: 31858345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass.
    Keaveny TM; Crittenden DB; Bolognese MA; Genant HK; Engelke K; Oliveri B; Brown JP; Langdahl BL; Yan C; Grauer A; Libanati C
    J Bone Miner Res; 2017 Sep; 32(9):1956-1962. PubMed ID: 28543940
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study.
    Inose H; Kato T; Tomizawa S; Ariga A; Motoyoshi T; Fukushima K; Takahashi K; Yoshii T; Okawa A
    Bone Rep; 2022 Dec; 17():101635. PubMed ID: 36389625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.